These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 12869391)

  • 1. The antianginal agent trimetazidine does not exert its functional benefit via inhibition of mitochondrial long-chain 3-ketoacyl coenzyme A thiolase.
    MacInnes A; Fairman DA; Binding P; Rhodes Ja; Wyatt MJ; Phelan A; Haddock PS; Karran EH
    Circ Res; 2003 Aug; 93(3):e26-32. PubMed ID: 12869391
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Beneficial effects of trimetazidine in ex vivo working ischemic hearts are due to a stimulation of glucose oxidation secondary to inhibition of long-chain 3-ketoacyl coenzyme a thiolase.
    Lopaschuk GD; Barr R; Thomas PD; Dyck JR
    Circ Res; 2003 Aug; 93(3):e33-7. PubMed ID: 12869392
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase.
    Kantor PF; Lucien A; Kozak R; Lopaschuk GD
    Circ Res; 2000 Mar; 86(5):580-8. PubMed ID: 10720420
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effects of chronic trimetazidine treatment on mechanical function and fatty acid oxidation in diabetic rat hearts.
    Onay-Besikci A; Guner S; Arioglu E; Ozakca I; Ozcelikay AT; Altan VM
    Can J Physiol Pharmacol; 2007 May; 85(5):527-35. PubMed ID: 17632588
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparison between ranolazine and CVT-4325, a novel inhibitor of fatty acid oxidation, on cardiac metabolism and left ventricular function in rat isolated perfused heart during ischemia and reperfusion.
    Wang P; Fraser H; Lloyd SG; McVeigh JJ; Belardinelli L; Chatham JC
    J Pharmacol Exp Ther; 2007 Apr; 321(1):213-20. PubMed ID: 17202401
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early administration of trimetazidine may prevent or ameliorate diabetic cardiomyopathy.
    Wenmeng W; Qizhu T
    Med Hypotheses; 2011 Feb; 76(2):181-3. PubMed ID: 20932648
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trimetazidine normalizes postischemic function of hypertrophied rat hearts.
    Saeedi R; Grist M; Wambolt RB; Bescond-Jacquet A; Lucien A; Allard MF
    J Pharmacol Exp Ther; 2005 Jul; 314(1):446-54. PubMed ID: 15840766
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protective effect of trimetazidine on myocardial mitochondrial function in an ex-vivo model of global myocardial ischemia.
    Monteiro P; Duarte AI; Gonçalves LM; Moreno A; Providência LA
    Eur J Pharmacol; 2004 Oct; 503(1-3):123-8. PubMed ID: 15496306
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment with the 3-ketoacyl-CoA thiolase inhibitor trimetazidine does not exacerbate whole-body insulin resistance in obese mice.
    Ussher JR; Keung W; Fillmore N; Koves TR; Mori J; Zhang L; Lopaschuk DG; Ilkayeva OR; Wagg CS; Jaswal JS; Muoio DM; Lopaschuk GD
    J Pharmacol Exp Ther; 2014 Jun; 349(3):487-96. PubMed ID: 24700885
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimizing cardiac energy metabolism: how can fatty acid and carbohydrate metabolism be manipulated?
    Lopaschuk GD
    Coron Artery Dis; 2001 Feb; 12 Suppl 1():S8-11. PubMed ID: 11286307
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardioprotective effects of trimetazidine: a review.
    Marzilli M
    Curr Med Res Opin; 2003; 19(7):661-72. PubMed ID: 14606990
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trimetazidine therapy prevents obesity-induced cardiomyopathy in mice.
    Ussher JR; Fillmore N; Keung W; Mori J; Beker DL; Wagg CS; Jaswal JS; Lopaschuk GD
    Can J Cardiol; 2014 Aug; 30(8):940-4. PubMed ID: 25064584
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Malonyl coenzyme a decarboxylase inhibition protects the ischemic heart by inhibiting fatty acid oxidation and stimulating glucose oxidation.
    Dyck JR; Cheng JF; Stanley WC; Barr R; Chandler MP; Brown S; Wallace D; Arrhenius T; Harmon C; Yang G; Nadzan AM; Lopaschuk GD
    Circ Res; 2004 May; 94(9):e78-84. PubMed ID: 15105298
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Medicines interacting with mitochondria: anti-ischemic effects of trimetazidine].
    Spedding M; Tillement JP; Morin D; Le Ridant A
    Therapie; 1999; 54(5):627-35. PubMed ID: 10667101
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Ischemic heart disease and left ventricular dysfunction: the role of trimetazidine].
    Belardinelli R
    Ital Heart J; 2004 Mar; 5 Suppl 2():23S-28S. PubMed ID: 15074774
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modulation of fatty acids oxidation in heart failure by selective pharmacological inhibition of 3-ketoacyl coenzyme-A thiolase.
    Fragasso G; Spoladore R; Cuko A; Palloshi A
    Curr Clin Pharmacol; 2007 Sep; 2(3):190-6. PubMed ID: 18690865
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ranolazine increases active pyruvate dehydrogenase in perfused normoxic rat hearts: evidence for an indirect mechanism.
    Clarke B; Wyatt KM; McCormack JG
    J Mol Cell Cardiol; 1996 Feb; 28(2):341-50. PubMed ID: 8729066
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic inhibition of fatty acid oxidation in right ventricular hypertrophy: exploiting Randle's cycle.
    Fang YH; Piao L; Hong Z; Toth PT; Marsboom G; Bache-Wiig P; Rehman J; Archer SL
    J Mol Med (Berl); 2012 Jan; 90(1):31-43. PubMed ID: 21874543
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ranolazine improves diastolic dysfunction in isolated myocardium from failing human hearts--role of late sodium current and intracellular ion accumulation.
    Sossalla S; Wagner S; Rasenack EC; Ruff H; Weber SL; Schöndube FA; Tirilomis T; Tenderich G; Hasenfuss G; Belardinelli L; Maier LS
    J Mol Cell Cardiol; 2008 Jul; 45(1):32-43. PubMed ID: 18439620
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolic modulators for chronic cardiac ischemia.
    Parang P; Singh B; Arora R
    J Cardiovasc Pharmacol Ther; 2005 Dec; 10(4):217-23. PubMed ID: 16382258
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.